440 related articles for article (PubMed ID: 24835192)
1. Efficacy of antibody-based therapies to treat Alzheimer's disease: just a matter of timing?
Cedernaes J; Schiöth HB; Benedict C
Exp Gerontol; 2014 Sep; 57():104-6. PubMed ID: 24835192
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
3. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.
Panza F; Solfrizzi V; Imbimbo BP; Giannini M; Santamato A; Seripa D; Logroscino G
Expert Rev Neurother; 2014 Sep; 14(9):973-86. PubMed ID: 25081412
[TBL] [Abstract][Full Text] [Related]
5. Amyloid beta peptide immunotherapy in Alzheimer disease.
Delrieu J; Ousset PJ; Voisin T; Vellas B
Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.
Panza F; Frisardi V; Imbimbo BP; Seripa D; Solfrizzi V; Pilotto A
Expert Opin Biol Ther; 2011 Jun; 11(6):679-86. PubMed ID: 21501112
[TBL] [Abstract][Full Text] [Related]
8. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.
Panza F; Solfrizzi V; Imbimbo BP; Tortelli R; Santamato A; Logroscino G
Expert Rev Clin Immunol; 2014 Mar; 10(3):405-19. PubMed ID: 24490853
[TBL] [Abstract][Full Text] [Related]
9. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.
Imbimbo BP; Ottonello S; Frisardi V; Solfrizzi V; Greco A; Seripa D; Pilotto A; Panza F
Expert Rev Clin Immunol; 2012 Feb; 8(2):135-49. PubMed ID: 22288451
[TBL] [Abstract][Full Text] [Related]
10. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
[TBL] [Abstract][Full Text] [Related]
12. Antibody-based therapy in Alzheimer's disease.
Pul R; Dodel R; Stangel M
Expert Opin Biol Ther; 2011 Mar; 11(3):343-57. PubMed ID: 21261567
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy for Alzheimer's disease].
Falkentoft AC; Hasselbalch SG
Ugeskr Laeger; 2016 Jan; 178(3):V07150588. PubMed ID: 26815584
[TBL] [Abstract][Full Text] [Related]
14. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?
Tayeb HO; Murray ED; Price BH; Tarazi FI
Expert Opin Biol Ther; 2013 Jul; 13(7):1075-84. PubMed ID: 23574434
[TBL] [Abstract][Full Text] [Related]
15. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.
Blennow K; Zetterberg H; Rinne JO; Salloway S; Wei J; Black R; Grundman M; Liu E;
Arch Neurol; 2012 Aug; 69(8):1002-10. PubMed ID: 22473769
[TBL] [Abstract][Full Text] [Related]
16. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
18. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS;
Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461
[TBL] [Abstract][Full Text] [Related]
19. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
Rygiel K
Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
[TBL] [Abstract][Full Text] [Related]
20. Solanezumab for Alzheimer's disease.
Samadi H; Sultzer D
Expert Opin Biol Ther; 2011 Jun; 11(6):787-98. PubMed ID: 21504387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
